Sacral neuromodulation may not work for everyone, but Axonics is hoping to more accurately identify those who may indeed be good candidates for the technology. The devicemaker has acquired a new ...

Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

In a report released on July 28, Anthony Petrone from Mizuho Securities reiterated a Buy rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $75.00. The ...

Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...

As Medtronic and Axonics’ legal battle over alleged similarities between their sacral neuromodulation devices drags on, Medtronic is getting the U.S. International Trade Commission involved. The ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) today and set a price target of $71.00. The company’s shares opened today at ...